Genenta Science S.p.A. is an Italian clinical-stage biotechnology firm focused on pioneering hematopoietic stem cell gene therapies to combat solid tumors. Its primary therapeutic candidate, Temferon, is currently undergoing Phase 1/2a clinical evaluation. This innovative therapy is being developed to treat glioblastoma multiforme, specifically targeting patients whose tumors exhibit an unmethylated MGMT gene promoter. Beyond this, Genenta Science is exploring Temferon's potential application in various other solid tumor types, including locally advanced hepatocellular carcinoma and intra-hepatic cholangiocarcinoma. Established in 2014, the company maintains its headquarters in Milan, Italy.
Genenta-backed Sòphia High Tech Brings Aerospace Precision Inside a Nuclear Fusion Reactor with ROMAN, a Robotic Arm
Genenta-backed Sòphia High Tech unveiled ROMAN, a robotic arm designed for inspection and maintenance inside nuclear fusion reactors, marking the portfolio company's entry into the nuclear domain.
The system was developed in collaboration with Herobots and the University of Naples to operate within the RFX-mod2 machine, handling extreme temperatures of approximately 20 million °C.
Genenta holds a 19% equity interest in Sòphia High Tech with an option to increase ownership to 51%, positioning this technological milestone as a validation of its strategic evolution into Saentra Forge.